Brokerages Set Perspective Therapeutics, Inc. (NYSE:CATX) Target Price at $20.00

Perspective Therapeutics, Inc. (NYSE:CATX) has earned an average rating of “Buy” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $20.00.

CATX has been the topic of a number of research reports. Lifesci Capital restated an “outperform” rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Oppenheimer reissued an “outperform” rating on shares of Perspective Therapeutics in a research note on Tuesday, June 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research note on Tuesday, June 25th. Bank of America began coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 price target on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price objective on shares of Perspective Therapeutics in a report on Friday, June 14th.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor bought 10,000 shares of Perspective Therapeutics stock in a transaction that occurred on Thursday, June 13th. The shares were purchased at an average price of $11.70 per share, with a total value of $117,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 13,757 shares in the company, valued at $160,956.90. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Johan M. Spoor bought 10,000 shares of the stock in a transaction that occurred on Thursday, June 13th. The stock was purchased at an average price of $11.70 per share, for a total transaction of $117,000.00. Following the completion of the purchase, the chief executive officer now owns 13,757 shares in the company, valued at approximately $160,956.90. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lori A. Woods purchased 4,587 shares of the business’s stock in a transaction on Friday, June 14th. The stock was acquired at an average price of $10.90 per share, for a total transaction of $49,998.30. Following the completion of the purchase, the director now owns 159,985 shares of the company’s stock, valued at $1,743,836.50. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 30,814 shares of company stock valued at $385,487. 3.52% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers purchased a new stake in shares of Perspective Therapeutics during the 2nd quarter worth approximately $630,000. Bank of New York Mellon Corp lifted its position in Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after acquiring an additional 93,548 shares during the last quarter. Virtu Financial LLC acquired a new position in Perspective Therapeutics in the first quarter valued at $138,000. Janus Henderson Group PLC acquired a new position in Perspective Therapeutics in the first quarter valued at $15,511,000. Finally, Affinity Asset Advisors LLC purchased a new position in shares of Perspective Therapeutics during the first quarter worth about $6,069,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Trading Down 1.5 %

NYSE CATX opened at $13.40 on Friday. Perspective Therapeutics has a twelve month low of $2.05 and a twelve month high of $19.05. The business’s fifty day simple moving average is $12.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.98 and a quick ratio of 12.98.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. The company had revenue of $0.33 million for the quarter. As a group, equities research analysts expect that Perspective Therapeutics will post -1.02 earnings per share for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.